Michael Yee
Stock Analyst at Jefferies
(2.80)
# 1,292
Out of 4,667 analysts
75
Total ratings
34.15%
Success rate
1.53%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Buy | $380 | $287.87 | +32.00% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $24.42 | +84.28% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $36.94 | +48.89% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $16.24 | +115.52% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $22.20 | +80.18% | 1 | Sep 13, 2024 | |
| AXON Axon Enterprise | Initiates: Buy | $385 | $609.82 | -36.87% | 4 | Jul 17, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $1.4 → $10 | $2.58 | +287.60% | 3 | Mar 27, 2024 | |
| CRGX CARGO Therapeutics | Maintains: Buy | $28 → $32 | $15.82 | +102.28% | 2 | Mar 22, 2024 | |
| IMRX Immuneering | Downgrades: Hold | $16 → $3 | $2.04 | +47.06% | 2 | Mar 15, 2024 | |
| BEAM Beam Therapeutics | Downgrades: Hold | $75 → $30 | $24.49 | +22.50% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $18 | $1.21 | +1,387.60% | 3 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $3 → $1 | $0.49 | +102.27% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $27.86 | -28.21% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $3 | $5.79 | -48.19% | 2 | Jul 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $18.20 | +312.09% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $340 | $451.23 | -24.65% | 3 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $350 | $156.00 | +124.36% | 4 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.72 | +1,644.19% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $32.42 | +100.49% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $45 | $0.35 | +12,757.14% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $2.41 | +1,144.81% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $14.40 | +108.33% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $15.02 | +698.93% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $19.17 | +291.24% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $14.04 | +113.68% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $11.45 | +572.49% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $88.63 | - | 3 | Jan 26, 2018 |
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $287.87
Upside: +32.00%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $24.42
Upside: +84.28%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $36.94
Upside: +48.89%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $16.24
Upside: +115.52%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $22.20
Upside: +80.18%
Axon Enterprise
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $609.82
Upside: -36.87%
Nuvation Bio
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.58
Upside: +287.60%
CARGO Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $28 → $32
Current: $15.82
Upside: +102.28%
Immuneering
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $2.04
Upside: +47.06%
Beam Therapeutics
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $24.49
Upside: +22.50%
Dec 8, 2023
Upgrades: Buy
Price Target: $8 → $18
Current: $1.21
Upside: +1,387.60%
Oct 25, 2023
Downgrades: Hold
Price Target: $3 → $1
Current: $0.49
Upside: +102.27%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $27.86
Upside: -28.21%
Jul 24, 2023
Downgrades: Hold
Price Target: $3
Current: $5.79
Upside: -48.19%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $18.20
Upside: +312.09%
Dec 19, 2022
Downgrades: Hold
Price Target: $340
Current: $451.23
Upside: -24.65%
Nov 30, 2022
Maintains: Buy
Price Target: $325 → $350
Current: $156.00
Upside: +124.36%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $1.72
Upside: +1,644.19%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $32.42
Upside: +100.49%
Mar 2, 2021
Downgrades: Hold
Price Target: $75 → $45
Current: $0.35
Upside: +12,757.14%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $2.41
Upside: +1,144.81%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $14.40
Upside: +108.33%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $15.02
Upside: +698.93%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $19.17
Upside: +291.24%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $14.04
Upside: +113.68%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $11.45
Upside: +572.49%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $88.63
Upside: -